Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous nano-fat is a liquid emulsion derived from a patient's own adipose tissue through a process of mechanical emulsification and filtration. Unlike traditional fat grafting, which focuses on volume replacement using intact adipocytes, the nano-fat process breaks down mature fat cells to create a fine, injectable substance rich in the stromal vascular fraction (SVF). This fraction contains a high concentration of adipose-derived stem cells (ADSCs), endothelial progenitor cells, and regenerative growth factors such as VEGF and TGF-beta. Nano-fat is primarily used for its regenerative and trophic effects, promoting angiogenesis, tissue repair, and collagen production. It is currently being investigated for a variety of clinical applications, including the treatment of chronic diabetic foot ulcers, androgenetic alopecia, musculoskeletal conditions, and aesthetic skin rejuvenation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous nano-fat.